Get the app
US › Healthcare

Zentalis Pharmaceuticals Llc (ZNTL)

US · Healthcare · Biotechnology

$3.08-0.65%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-77.6M
EPS
$-0.59
EPS estimate
$-0.45

EPS came in at -0.59 against a street estimate of -0.45 — a miss of 31.1%.

Key statistics

Market cap
$332.3M
Forward P/E
0.0
P/B
2.31
Book value
$2.00
EPS (TTM)
$-1.96
52-week high
$6.95
52-week low
$1.21
50-day MA
$4.31
200-day MA
$3.30
Beta
1.86

Analyst view

Analysts rate Zentalis Pharmaceuticals Llc a buy (4 buy, 6 hold, 0 sell out of 10) with an average price target of $6.89.

Shareholding

Insiders
21.88%
Institutions
50.89%

Largest institutional holders

FundStake
5AM Venture Management, LLC4.02%
Squadron Capital Management LLC3.77%
Two Sigma Investments LLC3.08%
Acadian Asset Management LLC2.90%
Vanguard Capital Management, LLC2.35%
Citadel Advisors Llc2.34%
Renaissance Technologies Corp1.98%
Opaleye Management Inc1.44%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zentalis Pharmaceuticals Llc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.